---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-035790"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:47:51.116490+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics discontinues CFT8634 BRD9 degrader; Q3 net loss $27.0M

## Summary
- CFT8634 Phase 1 dose escalation failed to show sufficient single-agent efficacy in synovial sarcoma and SMARCB1-null tumors despite high BRD9 degradation; wind-down by Q1 2024.
- Net loss $27.0M ($0.55 per share) vs $32.0M ($0.65) in Q3 2022; revenue $11.1M (up from $6.8M) from Roche and Biogen collaborations.
- Cash, equivalents and marketable securities $246.4M as of Sept 30, 2023; expected runway into H2 2025.
- CFT7455 Phase 1 dose escalation completed in monotherapy for R/R MM; combination arm continues; virtual event on Dec 12, 2023.
- Kendra Adams appointed CFO in September 2023.

## SEC filing metadata
- accession: 0001628280-23-035790
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828023035790/0001628280-23-035790-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828023035790/cccc-20231101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-035790
- JSON: https://secwatch.observer/filing/0001628280-23-035790.json
- Plain text: https://secwatch.observer/filing/0001628280-23-035790.txt

## Key facts
- Earnings Releases
  C4 Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 1, 2023, C4 Therapeutics, Inc. (the “ Company ”) issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828023035790/0001628280-23-035790-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.